← LIGAND PHARMACEUTICALS INC LGND
Market Price
$294.56
Market Cap
$5.78B
P/E Ratio
48.05
Revenue (FY 2025)
↑60.4% YoY
$268.09M
3-Yr CAGR: 11.0%
Net Income
↑3,186.6% YoY
$124.45M
Net Margin: 46.4%
Free Cash Flow
↓-48.6% YoY
$48.91M
FCF Yield: 0.85%
EPS (Diluted)
↑2,886.4% YoY
$6.13
Basic: $6.44
Return on Equity
Efficiency
12.2%
ROA: 15.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (LGND)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $109.0M | — | $96.1M | $-1.6M | — | $-0.08 | — | $63.0M | $61.2M | — |
| FY 2017 | $141.1M | +29.5% | $127.6M | $12.6M | +867.5% | $0.53 | +762.5% | $93.6M | $91.4M | +49.5% |
| FY 2018 | $251.5M | +78.2% | $203.2M | $143.3M | +1,041.5% | $5.96 | +1,024.5% | $194.1M | $193.2M | +111.3% |
| FY 2019 | $120.3M | -52.2% | $30.1M | $629.3M | +339.1% | $31.85 | +434.4% | $-29.3M | $-31.9M | -116.5% |
| FY 2020 | $186.4M | +55.0% | $90.3M | $-3.0M | -100.5% | $-0.18 | -100.6% | $54.6M | $50.1M | +257.2% |
| FY 2021 | $277.1M | +48.7% | $136.4M | $57.1M | +2,014.2% | $3.31 | +1,938.9% | $78.8M | $70.0M | +39.7% |
| FY 2022 | $196.2M | -29.2% | $73.1M | $-33.4M | -158.4% | $-1.98 | -159.8% | $137.8M | $119.9M | +71.2% |
| FY 2023 | $131.3M | -33.1% | $64.7M | $52.2M | +256.3% | $2.94 | +248.5% | $49.6M | $46.1M | -61.6% |
| FY 2024 | $167.1M | +27.3% | $56.0M | $-4.0M | -107.7% | $-0.22 | -107.5% | $97.0M | $95.2M | +106.8% |
| FY 2025 | $268.1M | +60.4% | $133.5M | $124.5M | +3,186.6% | $6.13 | +2,886.4% | $49.4M | $48.9M | -48.6% |
Valuation
Market Price
$294.56
Market Cap
$5.78B
Enterprise Value
N/A
P/E Ratio
48.05
P/B Ratio
5.80
FCF Yield
0.85%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
49.78%
Operating Margin
15.29%
Net Margin
46.42%
Return on Equity (ROE)
12.23%
Return on Assets (ROA)
14.95%
Asset Turnover
0.32x
Revenue 3-Yr CAGR
10.96%
Financial Health & Liquidity
Current Ratio
26.46
Cash Ratio
5.56
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$174.93M
Total Debt
N/A
Book Value / Share
$50.76
Cash Flow Efficiency
Operating Cash Flow
$49.36M
Capital Expenditures (CapEx)
$452.00K
Free Cash Flow
$48.91M
OCF / Revenue
18.41%
FCF / Revenue
18.24%
FCF 3-Yr CAGR
-25.84%
Per Share Metrics
EPS (Diluted)
$6.13
EPS (Basic)
$6.44
Dividends / Share
N/A
Book Value / Share
$50.76
EPS YoY Growth
2,886.36%
Balance Sheet (FY 2025)
Total Assets
$832.27M
Total Liabilities
$31.45M
Stockholders' Equity
$1.02B
Current Assets
$832.27M
Current Liabilities
$31.45M